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Much of the debate about the worth, or otherwise, of clinical
follow-up of patients after completion of their local and adjuvant
therapy for early breast cancer centres around the possible
survival benefits of this approach. The limited data, well
reviewed by Collins and coworkers [1], do not demonstrate any
survival advantage for follow-up. However, those authors
identified only five randomized trials addressing follow-up
questions, which between them contained 3,116 patients, and
so they cannot exclude absolute survival benefits of perhaps
4% or 5% for follow-up strategies. Death, like birth and taxes,
remains inevitable in life, and extension of the duration of life
justifies only some of what we do in the treatment of breast
cancer. For patients with early breast cancer that can be
treated by breast conservation, there remains no evidence that
this approach offers better survival than mastectomy, but few -
if any - would argue against offering women breast conser-
vation. Similarly, more than 6,000 patients were randomized in
the ATAC (Arimidex, Tamoxifen Alone or in Combination)
adjuvant trial [2], which compared anastrazole with tamoxifen in
postmenopausal women with early, hormone receptor positive
breast cancer, but there was not even a hint of a survival
advantage at over 5 years of follow-up for the use of
anastrazole rather than tamoxifen, but it is a widely accepted as
an appropriate treatment.
So, if we do not do clinical follow-up to improve survival, what
other advantages might there be, and what do accepted
guidelines suggest should be done?
Aiming at a North American audience, the American Society
for Clinical Oncology (ASCO) guidelines [3] state that, ‘The
evidence supports regular history, physical examination, and
mammography as the cornerstone of appropriate breast
cancer follow-up. Examinations should be performed every 3
to 6 months for the first 3 years, every 6 to 12 months for
years 4 and 5, and annually thereafter. For those who have
undergone breast-conserving surgery, a post-treatment mam-
mogram should be obtained 1 year after the initial mammo-
gram and at least 6 months after completion of radiation
therapy. Thereafter, unless otherwise indicated, a yearly
mammographic evaluation should be performed. The use of
[lots of tests] is not recommended for routine breast cancer
follow-up in an otherwise asymptomatic patient with no
specific findings on clinical examination.’
However, in the UK, the National Institute for Health and
Clinical Excellence (NICE) [4], presumably reviewing the
same data, concluded that, ‘Guidelines for limited (two or
three years) follow-up should be agreed by each network.
The aims of follow-up should be to detect and treat local
recurrence and adverse effects of therapy, particularly lymph-
oedema. Intensive follow-up, designed to detect metastatic
disease before symptoms develop, is not beneficial and
should not be provided.’
The only thing both guidelines seem to agree on is the futility
of conducting lots of intensive tests to try to detect
asymptomatic metastatic disease. What data are there to
support the NICE-endorsed limitation of follow-up to only 2 or
3 years, and to focus primarily on lymphoedema as the key
toxicity? Data from a retrospective analysis of 1,312 women
treated with breast conservation in Edinburgh between 1991
and 1998 suggested that only half of the ‘treatable
recurrences’ were detected mammographically [5]. Further-
more, that same study reported that although the peak
incidence of metastatic disease (the one thing that NICE
does not think we should be looking for in follow-up clinics)
was in the first 2 or 3 years, the risk for local (‘treatable’)
relapse was constant for at least the first 10 years! It would
therefore seem that the NICE guidance is inconsistent with
this study and much of the rest of the literature, in the sense
that limiting follow-up to the first 2 or 3 years does not appear
to maximize the chances of detecting and treating local
recurrence, with no data to support this recommendation
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provided in the paper summarizing the evidence base for the
2002 NICE recommendations!
Several authors have reviewed all of the data relating to
follow-up [1-6], but few have commented on one critical fact.
There is no doubt that the survival of women with early breast
cancer is improving. Furthermore, although there is debate as
to the relative contributions of screening, better preoperative
diagnostics, better local treatments and pathological assess-
ments, and the application of adjuvant therapies, it must be
recalled that all of the important studies were based on the
assumption that there would be regular and sustained clinical
follow-up. Furthermore, all of the randomized trials that
compare alternative methods of follow-up have included
some form of clinical follow-up in both arms. We therefore
ignore this consistent factor in all of those trials at our peril, in
the absence of any robust data indicating that follow-up is not
important in the treatment of our patients!
Thus, the question to be addressed is not really whether
there is any evidence to support ceasing clinical follow-up -
there is none. Until such a time that there is a properly
powered randomized trial that proves that there is no benefit
to patients from being reviewed clinically on a regular basis,
we have no evidence to stop doing what most of us, and
most of our patients, feel is appropriate - keeping in regular
clinical contact. However, the devil is in the detail, and the
debate really must focus around how patients can be
followed up, how frequently, for how long and what might be
the purpose of any follow-up. Table 1 summarises the issues.
Follow-up models
The traditional model is of frequent attendance at busy
clinics, usually with a consultant present; the reality, though,
is that patients are seen by frequently rotating junior staff.
This is reflected in data indicating that patients attending
hospital clinics see a median of 10 different doctors over
5 years of follow-up. Could this be better delivered in the
primary care sector? One trial randomized 296 patients
between follow-up in hospital or by specially trained general
practitioners [7,8]. No difference was found in time to
diagnosis of relapse or in quality of life, but the investigators
did report that patients being followed up in general practice
had more, and longer, visits than those in the secondary care
sector, but were more satisfied [7,8]. A subsequent, larger
study yielded similar findings [9]. A further study compared
different frequencies of follow-up and found that less frequent
follow-up was preferred by the majority of patients [10].
Should patients undergo regular mammography as part of
their follow-up? This is the recommendation of the ASCO
guidelines but not of the previous NICE guidelines. The
Ontario guidelines recognize that although there are no
randomized data to support this approach, there is
reasonable level C evidence to support its use to detect both
ipsilateral recurrence and contralateral second primary breast
cancer [11]. Organizing such regular mammography does not
need regular clinic visits but, unless for example it is done
within a systematic national breast screening programme, few
health care systems are currently in a position to provide this
service for breast cancer patients without being based within
a clinical structure.
So what sort of follow-up approach does make sense?
Montgomery and coworkers [12] reviewed the literature
available up to 2006 and concluded that, ‘There are no
randomised trials in the literature with sufficient power to
recommend an acceptable frequency or duration of follow up.
Moreover, there are no randomised trials that can confirm the
safety of using alternative follow-up methods.’ In essence,
Table 1
Summary of follow-up issues and evidence
Follow-up issues Summary of evidence
Survival advantage None reported but literature relatively underpowered
Doing no follow-up Never been tested in a randomized trial
ASCO guidance [3] Recommendations have not been tested in randomized controlled trials
NICE guidance [4] No evidence provided for the recommended limit of follow-up to 2 to 3 years
Local recurrence risk maintained for much longer than recommended follow-up period
Primary care follow-up Seems acceptable and good, but small trial (<300 patients) [7,8]
General practitioners needed training, and consultations take more time!
Telephone contact Some evidence from an unpublished small regional UK trial [15]
Nurses Acceptable to patients - not necessarily much cheaper
Nonpatient benefits Audit, research, measuring quality of service, identification of unexpected toxicities of new drugs
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they conclude that there is no real evidence for or against any
particular follow-up strategy. The NICE guidelines strongly
recommend indefinite access to a breast care nurse and that
issues of hormonal drug therapy should be left to general
practitioners. However, one study reported that up to 15% of
patients return to hospital-based clinics within a year of
discharge [13], so perhaps this non-clinic-based approach to
managing ongoing symptoms is not appropriate for all
patients! There are two studies that reported high levels of
patient satisfaction with a structured, prebooked, trained
nurse led telephone follow-up, combined with CA125 testing
in ovarian cancer [14] and with mammography in breast
cancer [15]. Thus, it may be that future provision of follow-up
will involve more use of technology and nurses, although the
latter are not necessarily much more economical than
involving junior doctors in the clinic!
A further consideration is the possible benefit for the health
care provider of follow-up, which will not be measured in
most studies. How can treating clinicians assess the quality
of their care, measure medium-term and long-term disease
outcome, cosmesis, satisfaction and toxicity of treatment
without being able to continue to assess the patients they
have treated? How can those planning health care provision
be sure that they are delivering optimal service if the
outcomes are unknown? What opportunity does discharge to
untrained general practitioner offer patients and their relatives
to discuss the finer details of their treatment, its toxicities, and
all of the implications to them and their families of a diagnosis
of breast cancer?
Finally, even NICE recognizes the importance of follow-up for
research protocols. At present in the UK, one patient is
enrolled to a study in breast cancer for every three or four
diagnosed with the disease, and so cessation of regular
follow-up for all but those included in trials will have less
impact on overall workload than is perhaps anticipated by
those health economists who recommend it! Furthermore, as
we move into an era of newer therapies, there may be
unexpected rare toxicities that will not be detected in a
modestly sized trial population, but only in larger national
datasets.
Conclusion
Our entire current evidence base for treating breast cancer
includes regular, sustained follow-up, and there are no data
that provide firm support for any particular level or method of
follow-up. Thus, the debate must be about how, where and by
whom follow-up should occur, and not about its worthless-
ness, until such time as a properly powered prospective trial
produces evidence to suggest that it is not worth doing from
any perspective!
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